Literature DB >> 11417748

Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.

H H Backus1, H M Pinedo, D Wouters, C M Kuiper, G Jansen, C J van Groeningen, G J Peters.   

Abstract

Thymidylate synthase (TS) is an important target for chemotherapy and can be inhibited by 5-fluorouracil (5-FU) and the antifolates, AG337 (Nolatrexed) and multitargeted antifolate (MTA or Pemetrexed). In addition, 5-FU can be incorporated into RNA and DNA, and MTA can inhibit two other enzymes. It is, however, unclear to what extent these differences in drug action will influence activation of downstream mechanisms mediated via TS inhibition. Therefore, two human colon cancer cell lines, WiDr and Lovo, with a different clonogenic origin, were treated with equitoxic concentrations of 5-FU, AG337, and MTA to determine the induction of DNA damage, cell cycle arrest, downstream protein expression, and cell death. At these concentrations, the specific TS inhibitor AG337 induced more DNA damage (up to 20%) than MTA and 5-FU. FACS analysis showed that all drugs induced S phase arrest in Lovo and WiDr that was most pronounced after 5-FU and AG337 exposure (50-70%). Western blotting showed that p53 induction was not detectable in mutant (mt) p53 WiDr and increased much earlier in wild-type (wt) Lovo cells after 5-FU and MTA (24 h) than after AG337 exposure (72 h). In contrast to 5-FU-treated Lovo cells, the bcl-2/bax ratio decreased after antifolate exposure. Nevertheless, both 5-FU and antifolates induced similar amounts of cell death (up to 60%). These results demonstrate that in human colon cancer cells differences in downstream events between AG337 and 5-FU or MTA are related to the additional effects of 5-FU and MTA, which are not associated with TS inhibition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11417748     DOI: 10.3727/096504001108747729

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  8 in total

1.  Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks.

Authors:  Norihiko Suzuki; Fumio Nakagawa; Mamoru Nukatsuka; Masakazu Fukushima
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

2.  Hepatoprotective Activity of Gentisic Acid on 5-Fluorouracil-induced Hepatotoxicity in Wistar Rats

Authors:  Rohini Revansiddappa Pujari; Deepti Dinesh Bandawane
Journal:  Turk J Pharm Sci       Date:  2021-06-18

3.  Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression.

Authors:  Alessio Ligabue; Gaetano Marverti; Ursula Liebl; Hannu Myllykallio
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

4.  Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression.

Authors:  Zhengyu Fang; Wantong Yao; Yi Xiong; Jiana Li; Li Liu; Lei Shi; Wei Zhang; Chao Zhang; Liping Nie; Jun Wan
Journal:  BMC Cancer       Date:  2011-05-24       Impact factor: 4.430

5.  Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity.

Authors:  J L Fischel; P Formento; J Ciccolini; P Rostagno; M C Etienne; J Catalin; G Milano
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

6.  Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.

Authors:  C Tekle; E Giovannetti; J Sigmond; J R Graff; K Smid; G J Peters
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

7.  Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells.

Authors:  J Yan; N Zhong; G Liu; K Chen; X Liu; L Su; S Singhal
Journal:  Cell Death Dis       Date:  2014-07-03       Impact factor: 8.469

8.  The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.

Authors:  Xinyuan Ding; Yuting Gu; Min Jin; Xin Guo; Sudong Xue; Caihong Tan; Jiefang Huang; Wanlin Yang; Mingxing Xue; Qianjun Zhou; Wenjuan Wang; Yanyun Zhang
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.